🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Egypt / NCT06702787
Enrolling by invitation Observational

Mechanical Thrombectomy in the Middle East and North Africa: Interim Results from the MEMENTO Registry

NCT06702787 · tracked via the Priya Life Science Egypt tracker
Phase
Observational
Started
2022-03-11
Last updated
2024-11-25

Condition(s) studied

StrokeStroke AcuteEndovascular ProceduresLarge Vessel Occlusion

Study summary

The MEMENTO (MEchanical thrMobectomy NETwork for MENA TOgether) Registry is a multicenter, prospective observational study aiming to evaluate the effectiveness, safety, and cost-effectiveness of mechanical thrombectomy (MT) in patients with acute ischemic stroke (AIS) due to large vessel occlusions (LVO) in the Middle East and North Africa (MENA) region. This interim analysis reports on the first 499 patients enrolled, assessing clinical outcomes, procedural details, and economic implications.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: Adults aged 18 years and older (no upper age limit). Diagnosed with acute ischemic stroke due to confirmed large vessel occlusion (LVO) or medium vessel occlusion (MeVO). Underwent mechanical thrombectomy (MT) with or without prior intravenous thrombolysis (IV tPA). Pre-stroke modified Rankin Scale (mRS) score of 0-5. Consent to participate in the registry (by patient or legal representative). Exclusion Criteria: Absence of confirmed LVO or MeVO. Pre-stroke mRS score of 6. Known severe comorbid conditions precluding MT. Inability to obtain informed consent. Patients not treated with MT.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Alexandria University Stroke network Alexandria Alexandria Governorate

More Middle East North Africa Stroke and Interventional Neurotherapies Organization trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06702787 on ClinicalTrials.gov ↗ ← All trials in Egypt